Masimo (MASI) Stock Price, News & Analysis

Company Overview

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications. The company has expanded into consumer health with wearable devices capable of measuring oxygen saturation, pulse rate, and other vital signs, supporting the growing trend toward home-based care and telehealth. Masimo’s software solutions enable real-time data analytics and alerts, allowing clinicians to detect patient deterioration earlier and improve workflow efficiency.

Headquartered in Irvine, California, Masimo operates in more than 100 countries through a combination of direct sales forces, distributors, and strategic partnerships. Key markets include North America, Europe, Asia-Pacific, and Latin America, where its products are used in hospitals, surgical centers, and home health environments. The company has established regional offices in Europe, the Middle East, and Asia to support local regulatory approvals and provide customer training and technical service.

Founded in 1989 by Joe Kiani, who serves as chairman and chief executive officer, Masimo has built a reputation for innovation and has received numerous industry awards. Under Kiani’s leadership, the company has invested heavily in research and development, filing hundreds of patents to advance noninvasive monitoring technology. This focus on innovation and quality has driven Masimo’s growth and positioned it as a leader in patient monitoring worldwide.

Key Stats

• Today's Range: $178.25 to $178.74
• 50-Day Range: $175.10 to $178.73
• 52-Week Range: $125.94 to $179.00
• Volume: 632,566 shs
• Average Volume: 1.40 million shs
• Market Capitalization: $9.32 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $181.17
• Consensus Rating: Reduce

Masimo Stock Analysis - MarketRank™

Masimo scored higher than 26% of companies evaluated by MarketBeat, and ranked 740th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Reduce

Consensus Rating

Masimo has received a consensus rating of Reduce. The company's average rating score is 1.89, and is based on no strong buy ratings, no buy ratings, 8 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Masimo is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Masimo has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 10.23%

Earnings Growth

Earnings for Masimo are expected to grow by 10.23% in the coming year, from $5.77 to $6.36 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Masimo is -16.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Masimo is -16.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Masimo has a PEG Ratio of 1.81. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Masimo has a P/B Ratio of 13.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.87% of the float of Masimo has been sold short.

Short Interest Ratio / Days to Cover

Masimo has a short interest ratio ("days to cover") of 5.47.

Change versus previous month

Short interest in Masimo has recently increased by 17.58%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Masimo does not currently pay a dividend.

Dividend Growth

Masimo does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.56

News Sentiment

Masimo has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Masimo this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for MASI on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Masimo to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Masimo insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.90% of the stock of Masimo is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

85.96% of the stock of Masimo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MASI Stock Analysis - Frequently Asked Questions

How have MASI shares performed this year?

Masimo's stock was trading at $130.06 at the beginning of 2026. Since then, MASI stock has increased by 37.2% and is now trading at $178.4850.

How were Masimo's earnings last quarter?

Masimo Corporation (NASDAQ:MASI) issued its quarterly earnings results on Tuesday, November, 4th. The medical equipment provider reported $1.32 EPS for the quarter, topping analysts' consensus estimates of $1.20 by $0.12. The business's revenue was up 8.2% on a year-over-year basis.
Read the conference call transcript.

Who are Masimo's major shareholders?

Masimo's top institutional shareholders include SG Americas Securities LLC (0.97%), Hsbc Holdings PLC (0.88%), Bank of New York Mellon Corp (0.57%) and Principal Financial Group Inc. (0.19%). Insiders that own company stock include Joe E Kiani, Bilal Muhsin, Craig B Reynolds, Michelle Brennan and William R Jellison.
View institutional ownership trends.

How do I buy shares of Masimo?

Shares of MASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Masimo investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/04/2025
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:MASI
• CIK: 937556
• Web: www.masimo.com
• Phone: (949) 297-7000
• Fax: 949-297-7001
• Employees: 2,200
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Masimo: $181.17
• High Price Target: $200.00
• Low Price Target: $162.00
• Potential Upside/Downside: +1.5%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($10.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 30.94
• P/E Growth: 1.81
• Net Income: -$151.50 million
• Net Margins: -9.92%
• Pretax Margin: 17.85%
• Return on Equity: 32.02%
• Return on Assets: 13.73%

Debt

• Debt-to-Equity Ratio: 0.72
• Current Ratio: 2.49
• Quick Ratio: 1.47

Sales & Book Value

• Annual Sales: $1.53 billion
• Price / Sales: 6.10
• Cash Flow: $4.65 per share
• Price / Cash Flow: 38.37
• Book Value: $13.43 per share
• Price / Book: 13.29

Miscellaneous

• Outstanding Shares: 52,190,000
• Free Float: 44,636,000
• Market Cap: $9.32 billion
• Optionable: Optionable
• Beta: 1.13